Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: three-year follow-up data of a single-blind randomised controlled trial.
Astrid M van HuizenG E van der KraaijC I BusardW OuwerkerkJuul M P A van den ReekS P MentingE PrensT RispensA de VriesE M G J de JongJ LambertM B A van DoornPh I SpulsPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
In this small study, there was no significant difference in ADL overall drug survival when it was initially combined with MTX, compared to ADL alone. Discontinuation due to adverse events was common in the combination group. To secure accessible healthcare, combination treatment of ADL and MTX can be considered in individual patients.